Office of Technology Development | The University of Oklahoma

OTD Home | OU Home | OUHSC Home | OU Tulsa Home

ANNOUNCEMENT: Equity Management Committee Meeting Scheduled for Nov. 7.

Synthetic Vitamin A retinoid compound effective against cancer, polycystic kidney disease
A synthetic Vitamin A retinoid compound that induces potent apoptosis, a natural form of cell suicide in cancer cells, but that, unlike current cancer therapies, is not toxic to healthy cells ... read more

	Tyrell Conway Using cutting-edge technology called microarrays read more about this inventor
	Edgar O'Rear cotton fabric that is water repellent while still retaining its most desirable features read more about this inventor

Selexys Pharmaceuticals Corp.

Selexys Pharmaceuticals Corp. is a privately held company that develops and commercializes therapeutics to treat inflammatory and thrombotic diseases.

The company has completed research and is in preclinical development of two drug candidates, a monoclonal antibody and a glycosulfopeptide, that have broad application for the treatment of acute and chronic inflammatory disorders.

Company Web site

Norman Campus
Three Partners Place
201 David L. Boren Blvd., Suite 100
Norman, Oklahoma 73019-5710
Tel: (405) 325-3800
Fax: (405) 325-7162

OU Health Sciences Center Campus
755 Research Parkway, Suite 429
Oklahoma City, OK 73104
Tel: (405) 271-7725
Fax: (405) 271-3555